路透7月9日 - 阿斯利康 AZN.L 周四表示,其与Ionis IONS.O 合作研发的药物Wainua在后期临床试验中未能达到降低心血管死亡率和心血管疾病复发率这一主要目标。
路透7月9日 - 阿斯利康 AZN.L 周四表示,其与Ionis IONS.O 合作研发的药物Wainua在后期临床试验中未能达到降低心血管死亡率和心血管疾病复发率这一主要目标。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.